Claims for Patent: 11,883,526

Summary for Patent: 11,883,526

Title:	Esketamine for the treatment of depression
Abstract:	The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.
Inventor(s):	Jaskaran Singh, Ella Daly, Margaret Fedgchin, David Hough, Vanina Popova
Assignee:	Janssen Pharmaceutica NV , Janssen Research and Development LLC
Application Number:	US17/711,277
Patent Claims:	1. A method of treating major depressive disorder in a human patient in need thereof based on a dosing regimen, said regimen having an induction phase and, a subsequent maintenance phase, wherein the induction phase has a duration of 4 weeks, the method comprising: intranasally administering an aqueous formulation comprising esketamine and/or a pharmaceutically acceptable salt thereof in the induction phase to provide a therapeutically effective amount of about 56 mg or about 84 mg of esketamine per induction phase treatment session to the patient, wherein the induction phase treatment session occurs at a frequency of twice weekly during the induction phase; and intranasally administering an aqueous formulation comprising esketamine and/or a pharmaceutically acceptable salt thereof in the maintenance phase to provide a therapeutically effective amount of about 56 mg or about 84 mg of esketamine per maintenance phase treatment session to the patient, wherein the maintenance phase treatment session occurs at a frequency of once weekly or once every other week during the maintenance phase; and wherein the patient has a worsening of depression symptoms following a missed treatment session during the maintenance phase and is returned to a previously higher frequency of treatment session before the missed treatment session. 2. The method of claim 1, wherein the missed treatment session is a once weekly treatment session, and the patient is returned to twice weekly treatment session. 3. The method of claim 1, wherein the missed treatment session is a once every other week treatment session, and the patient is returned to once weekly treatment session. 4. The method of claim 1, further comprising adjunctive treatment with a therapeutically effective amount of one or more antidepressants during the induction phase or the maintenance phase. 5. The method of claim 1, further comprising adjunctive treatment with a therapeutically effective amount of one or more antidepressants during the induction phase and the maintenance phase. 6. The method of claim 5 wherein the one or more antidepressants is an oral antidepressant. 7. The method of claim 1, wherein the major depressive disorder is major depressive disorder with suicidal ideation or behavior. 8. The method of claim 1, wherein the major depressive disorder is treatment resistant depression. 9. The method of claim 1, wherein the aqueous formulation comprises esketamine hydrochloride during the induction phase and maintenance phase. 10. The method of claim 2, wherein the major depressive disorder is treatment resistant depression. 11. The method of claim 10, wherein the aqueous formulation comprises esketamine hydrochloride during the induction phase and maintenance phase. 12. The method of claim 10, further comprising adjunctive treatment with a therapeutically effective amount of one or more antidepressants during the induction phase or the maintenance phase. 13. The method of claim 10, further comprising adjunctive treatment with a therapeutically effective amount of one or more antidepressants during the induction phase and the maintenance phase. 14. The method of claim 13 wherein the one or more antidepressants is an oral antidepressant. 15. The method of claim 14, wherein the aqueous formulation comprises esketamine hydrochloride during the induction phase and maintenance phase. 16. The method of claim 2, wherein the major depressive disorder is major depressive disorder with suicidal ideation or behavior. 17. The method of claim 16, wherein the aqueous formulation comprises esketamine hydrochloride during the induction phase and maintenance phase. 18. The method of claim 16, further comprising adjunctive treatment with a therapeutically effective amount of one or more antidepressants during the induction phase or the maintenance phase. 19. The method of claim 16, further comprising adjunctive treatment with a therapeutically effective amount of one or more antidepressants during the induction phase and the maintenance phase. 20. The method of claim 19 wherein the one or more antidepressants is an oral antidepressant. 21. The method of claim 20, wherein the aqueous formulation comprises esketamine hydrochloride during the induction phase and maintenance phase. 22. The method of claim 3, wherein the major depressive disorder is treatment resistant depression. 23. The method of claim 22, wherein the aqueous formulation comprises esketamine hydrochloride during the induction phase and maintenance phase. 24. The method of claim 22, further comprising adjunctive treatment with a therapeutically effective amount of one or more antidepressants during the induction phase or the maintenance phase. 25. The method of claim 22, further comprising adjunctive treatment with a therapeutically effective amount of one or more antidepressants during the induction phase and the maintenance phase. 26. The method of claim 25 wherein the one or more antidepressants is an oral antidepressant. 27. The method of claim 26, wherein the aqueous formulation comprises esketamine hydrochloride during the induction phase and maintenance phase. 28. The method of claim 3, wherein the major depressive disorder is major depressive disorder with suicidal ideation or behavior. 29. The method of claim 28, wherein the aqueous formulation comprises esketamine hydrochloride during the induction phase and maintenance phase. 30. The method of claim 28, further comprising adjunctive treatment with a therapeutically effective amount of one or more antidepressants during the induction phase or the maintenance phase. 31. The method of claim 28, further comprising adjunctive treatment with a therapeutically effective amount of one or more antidepressants during the induction phase and the maintenance phase. 32. The method of claim 31 wherein the one or more antidepressants is an oral antidepressant. 33. The method of claim 32, wherein the aqueous formulation comprises esketamine hydrochloride during the induction phase and maintenance phase.